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An EPidEMiologic ModEling APPlicAtion to PhARMAcoEconoMics foR 
iMPRovEd hEAlth cARE PlAnning
Cid Ruzafa J., Cox A., Merinopoulou E., Baggaley R., Leighton P., Desai K.
Evidera, London, UK
Epidemiologic and pharmacoeconomic models differ in terms of populations con-
sidered, mathematical techniques used, and questions addressed. A typical pharma-
coeconomic model assesses chronic or acute conditions, uses Markov techniques, 
and considers a closed patient group receiving a defined therapy to assess incre-
mental costs needed to achieve gains in quality adjusted life years. A typical epide-
miologic model assesses vaccination or public health interventions for infectious 
disease using differential equations and considers open populations representing 
communities to estimate prevalence or numbers of disease cases averted. The man-
ner of conducting sensitivity analyses also differs. In oncology, in which multiple 
lines of treatment are available, the epidemiologic approach has application to esti-
mate the patient point prevalence or the number of patients who can start on a line 
of therapy over a certain time period, when this cannot be determined from clinical 
trials or registers (which usually focus on single lines of therapy or limited types of 
patients that are not representative of the overall patient population). The approach 
consists of conceptualizing an open population that incorporates incidence of the 
condition and the transition of patients through various lines of treatment until 
death, and uses systems of difference/differential equations. Parameterization is 
challenging if there are several prognostic factors to describe the patient population, 
multiple or complex treatment pathways, and a wide range of variability. Parameters 
are obtained from the published literature, analyses of database information, and/
or surveys to experts in the field. Steady state solutions of the model equations 
estimate point and period prevalence. This approach is applicable to gastrointesti-
nal stromal tumours and multiple myeloma. Resulting estimates are important for 
budget impact analysis and health care services planning by reducing uncertainty 
associated with identifying the patient numbers eligible for a given treatment. 
Epidemiologic modelling permits a framework to estimate disease prevalence that 
is little used in pharmacoeconomics.
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non-intERvEntionAl REsEARch EthicAl REquiREMEnts in EnglAnd And 
fRAncE: shAREd ExPERiEncE fRoM A BinAtionAl REsEARch PRojEct
Guillemot J., Boval M.C., Gauthier A.
Amaris, London, UK
BAckground: Ethical review for non-interventional research is progressively becom-
ing part of research standards. This evolution ensures that participants in research 
are respectfully considered. In practice, information on ethical requirements for non-
interventional research seems insufficient. Increasing and legitimate expectations 
from peer-reviewed journals regarding reviews by ethics committees sometimes 
challenge researchers. In this presentation, we share our experience of investigating 
ethical requirements for conducting a questionnaire-based research on physicians in 
France and England. Methods: This investigation consisted of a documentary analy-
sis, including official guidance documents on ethical requirements, communications 
with institutions and publications reviews. Documents were identified using an ad 
hoc search on official websites. Publications were identified on PubMed. Findings: 
In England, the service of the National Research Ethics Service (NRES) serves as the 
ethics reviewer. It offers an informal preliminary review of the study protocol and esti-
mates ethical risks associated with non-interventional research projects. Depending 
of the target population, the methods and the risk level associated with the research 
project, the NRES states whether a formal ethics application is necessary or not. In 
case of low risk projects the NRES supplies an email which can be used as a justifica-
tion for peer-reviewed journals. In France, structures to support ethical reviews for 
non-interventional research are the result of an on-going reform. Comités de Protection 
de la Personne, or CPPs, fulfil the role of ethics reviewers although they were initially 
designed to collaborate for hospital-based research. Gaining ethical review in France 
was more complex due to the infrequent character of such request from the indus-
try. conclusion: This experience showed the increasing role of ethical require-
ments in non-interventional research. It is a domain in constant movement which 
calls for innovative approaches to compile and disseminate information regarding 
ethical requirements for non-interventional research across Europe and the world, 
especially regarding cross-national research projects.
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REAl WoRld studiEs, chAllEngEs, nEEds And tREnds fRoM thE 
industRy
Batrouni M., Comet D., Meunier J.P.
Axonal, Paris, France
oBjectives: To understand key challenges, needs and trends for conducting real 
world studies (RWS). Methods: An online survey conducted in September 2013 
within key players in the pharmaceutical and medical device industry in EU and US. 
456 persons have been solicited through emails and phone calls, 107 have responded 
to the questionnaire. Respondents were mostly occupying senior positions in medi-
cal affairs, health economics and outcome research. results: 27% RWS conducted 
are requested by Health Authorities, 73% on the industry initiative. 75% of those 
studies are subcontracted to a CRO. The main criteria of choice are the experience 
in RWS, particularly in the regulation process, the capacity to deliver on time and a 
flexible and adaptable structure. The RWS activity is expected to increase by 25 % in 
the next two years. Most of those studies have safety and effectiveness objectives 
and to a lesser extent drug utilization and health economics and the most common 
therapeutic areas are: oncology, cardiovascular and metabolic disorders. In addition, 
pharmaceutical companies are conducting more and more epidemiological studies 
to prepare dossiers for market access (disease understanding, unmet needs, popula-
tion targeting). conclusion: The pharmaceutical market is becoming global and 
is expanding into new countries and therapeutic areas. The result is an increase 
in the need for RWS where the regulatory agencies are asking for additional data 
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PAthWAys of iMPlEMEntAtion of Multi-cRitERiA dEcision AnAlysis 
into oRPhAn dRug APPRovAl PRocEduRE foR dRug suPPly PRogRAMs in 
RussiAn fEdERAtion
Serpik V.G.1, Yagudina R.I.2
1National Research Institute of Public Health, Moscow, Russia, 2First Moscow State Medical 
University named after I. M. Sechenov, Moscow, Russia
BAckground: While the orphan drug supply program is in progress, development 
of decision-making rules for approving orphan drug for supply program of Russian 
Federation becomes very actual. Real world data provides evidence, that routine 
approaches for approving such kind of drugs, e.i. pharmacoeconomic conclusions, 
are not applicable. Than the need in more appropriate approaches is existed. 
Multi-criteria decision analysis is one such approaches (MCDA). oBjective: To 
evaluate prospective of implementation of MCDA in health care system of Russian 
Federation and to develop road map of MCDA in Russia. Methods: Literature 
review, cluster analysis, interviewing experts. results: The first step (qualitive) 
to implement MCDA is to test various MCDA methods to find out optimal one for 
Russian Federation: it is expected to select the most relevant criteria from the wide 
range of them. First of all, MCDA is considered to be the instrument to improve the 
quality of discussion and its transparency, to underline different point of view and 
unmet needs. On the second stage it may be possible to use quantity MCDA assess-
ment as a rule to approve orphan drugs for drug supply programs. Local recom-
mendations for MCDA in Russian Federation has been published. conclusion: 
Implementation of MCDA as assisting instrument for orphan drug approving for 
drug supply programs is likely to be a valuable approach, that may improve the 
quality, transparency of decision-making process and to provide social equity for 
accepting decisions.
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PRoPEnsity scoRE MAtching And suBclAssificAtion With Multi-lEvEl 
tREAtMEnts
Kadziola Z.1, Yang S.2, Imbens G.W.3, Cui Z.4, Faries D.E.4
1Eli Lilly Regional Operations GmbH, Vienna, Austria, 2Harvard School of Public Health, Boston, 
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There is extensive literature on methods, such as propensity scoring, for esti-
mating the causal effects for two treatments using real world data. Much less 
work has been done for the more general setting with three or more treatments. 
Whereas the literature has suggested that these propensity-based methods do 
not naturally extend to the multi-level treatment case, we show, using the con-
cept of weak unconfoundedness, that adjusting for or matching on a scalar func-
tion of the covariates removes biases associated with observed covariates. We 
focused on subclassification and matching approaches as these have found to 
be effective for two treatments and are among the most popular methods in 
that setting. We apply the proposed methods to an analysis of the effectiveness 
of treatments for fibromyalgia from a prospective observational study. We also 
carried out a simulation study to assess the performance of those new methods 
relative to such approaches like: pairwise propensity score matching; matching 
on the Mahalanobis distance of all covariates; matching on the set of propensity 
scores (with the number of scores equal to the number of distinct treatment lev-
els minus one (Rassen, 2013)); weighting on the inverse of the binary treatment 
propensity scores (McCaffrey, 2013). The simulations suggest that the proposed 
methods are simple and viable options for comparing the effectiveness of three 
or more treatments. RASSEN et al.: Matching by propensity score in cohort studies 
with three treatment groups. Epidemiology 24, 401–9. MCCAFFREY et al.: A tutorial 
on propensity score estimation for multiple treatments using generalized boosted 
models. Stat. Med. 32,3388–414.
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Alsop J.
Numerus Ltd, Wokingham, UK
Reimbursement authorities often require pharmaceutical companies to provide 
them with more than just placebo-controlled data from RCTs. Instead, they typi-
cally seek data from a wider “real-world” setting, where the focus is on generating 
evidence of comparative effectiveness. The natural temptation for many phar-
maceutical companies is to provide this evidence from separate, post-market 
approval studies. However, this approach can be expensive and undoubtedly leads 
to delays in reimbursement. We propose that both the additional costs of evidence 
gathering and the delays between regulatory and reimbursement approvals could 
be reduced by combining the main design elements of randomised, pragmatic, 
and prospective observational studies into a single, integrated Phase 3/4 study. 
This single study approach would typically begin with a standard RCT phase 
where, for example, an initial cohort of patients would be randomised to receive 
either the investigational therapy or placebo. Either in parallel with or follow-
ing this phase, a second patient cohort would be randomised under pragmatic 
clinical trial conditions with the aim of comparing the investigational therapy 
with placebo and a limited number of active comparator treatments. Lastly, a 
third (observational) cohort would be enrolled and allocated to a wider range 
of therapies, as per clinical practice. Data from the RCT cohort would be used 
to obtain limited regulatory approval. Following this, data from the pragmatic 
cohort, once available, would then be formally combined using standard statistical 
techniques with data from the RCT cohort in order to obtain a wider regulatory 
approval and possibly some form of conditional reimbursement. The pragmatic 
and observational cohorts would then provide the comparative effectiveness 
data to allow for reimbursement across different patient groups. We outline the 
strengths and weaknesses of this approach, and discuss its operational consid-
erations.
